Published • loading... • Updated
AbbVie Adds 340B CP Restrictions to New Blood Cancer Drug
Summary by 340breport.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
AbbVie Adds 340B CP Restrictions to New Blood Cancer Drug
AbbVie recently announced 340B contract pharmacy restrictions for its new federally approved drug used to treat Blastic plasmacytoid dendritic cell AbbVie announced 340B contract pharmacy restrictions for its new federally approved drug used to treat a rare and aggressive form of blood cancer.
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
